From Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, and Saint Luke's Mid-America Heart Institute, Kansas City, Missouri.
Ann Intern Med. 2018 Jan 16;168(2):93-99. doi: 10.7326/M17-1058. Epub 2017 Dec 5.
Limited data suggest high rates of unplanned rehospitalization after endovascular and surgical revascularization for peripheral arterial disease. However, the overall burden of readmissions has not been comprehensively explored.
To evaluate nationwide readmissions after peripheral arterial revascularization for peripheral arterial disease and to assess whether readmission risk varies among hospitals.
Retrospective cohort study.
1085 U.S. acute care hospitals participating in the Nationwide Readmissions Database.
61 969 unweighted hospitalizations of patients with peripheral arterial disease who had peripheral arterial revascularization and were discharged alive between 1 January and 30 November 2014.
30-day readmission rates, causes, and costs of unplanned rehospitalizations after peripheral arterial revascularization; 30-day risk-standardized readmission rates (RSRRs), calculated using hierarchical logistic regression, to assess for heterogeneity of readmission risk between hospitals.
Among 61 969 hospitalizations of patients with peripheral arterial disease who were discharged alive after peripheral arterial revascularization, the 30-day nonelective readmission rate was 17.6%. The most common cause of readmission was procedural complications (28.0%), followed by sepsis (8.3%) and complications due to diabetes mellitus (7.5%). Among rehospitalized patients, 21.0% underwent a subsequent peripheral arterial revascularization or lower extremity amputation, 4.6% died, and the median cost of a readmission was $11 013. Thirty-day RSRRs varied from 10.0% to 27.3% (interquartile range, 16.6% to 18.8%).
Inability to distinguish out-of-hospital deaths after discharge and potential misclassification bias due to use of billing codes to ascertain diagnoses and interventions.
More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arterial revascularization have unplanned readmission within 30 days, with high associated mortality risks and costs. Procedure- and patient-related factors were the primary reasons for readmission. Readmission rates varied moderately between institutions after hospital case mix was accounted for, suggesting that differences in hospital quality may only partially account for readmission.
Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center.
有限的数据表明,在外周动脉疾病的血管内和手术血运重建后,计划性再入院率较高。然而,总体再入院负担尚未得到全面探讨。
评估外周动脉血运重建后外周动脉疾病的全国范围内再入院情况,并评估再入院风险是否在各医院之间存在差异。
回顾性队列研究。
参与全国再入院数据库的 1085 家美国急性护理医院。
2014 年 1 月 1 日至 11 月 30 日期间,61969 例接受外周动脉血运重建且存活出院的外周动脉疾病患者的未经加权住院。
外周动脉血运重建后计划性再入院的 30 天再入院率、原因和费用;使用分层逻辑回归计算 30 天风险标准化再入院率(RSRR),以评估医院之间再入院风险的异质性。
在 61969 例接受外周动脉血运重建且存活出院的外周动脉疾病患者的住院中,30 天非计划性再入院率为 17.6%。再入院的最常见原因是手术并发症(28.0%),其次是败血症(8.3%)和糖尿病并发症(7.5%)。在再入院患者中,21.0%接受了后续的外周动脉血运重建或下肢截肢,4.6%死亡,再入院的中位费用为 11013 美元。30 天 RSRR 从 10.0%到 27.3%不等(四分位距,16.6%至 18.8%)。
无法区分出院后的院外死亡,并且由于使用计费代码来确定诊断和干预,可能存在潜在的分类偏倚。
超过 1/6 的接受外周动脉血运重建的外周动脉疾病患者在 30 天内计划性再入院,且相关死亡率和费用高。与手术和患者相关的因素是再入院的主要原因。在考虑到医院病例组合后,各机构之间的再入院率存在适度差异,这表明医院质量的差异可能仅部分解释了再入院的原因。
Smith 中心心脏康复结局研究,贝斯以色列女执事医疗中心。